BRPI0914666A2 - otimização da solubilidade de ligantes imunológicos - Google Patents

otimização da solubilidade de ligantes imunológicos

Info

Publication number
BRPI0914666A2
BRPI0914666A2 BRPI0914666A BRPI0914666A BRPI0914666A2 BR PI0914666 A2 BRPI0914666 A2 BR PI0914666A2 BR PI0914666 A BRPI0914666 A BR PI0914666A BR PI0914666 A BRPI0914666 A BR PI0914666A BR PI0914666 A2 BRPI0914666 A2 BR PI0914666A2
Authority
BR
Brazil
Prior art keywords
optimization
immunological ligand
ligand solubility
solubility
immunological
Prior art date
Application number
BRPI0914666A
Other languages
English (en)
Inventor
David Urech
Leonardo Borras
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914666(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of BRPI0914666A2 publication Critical patent/BRPI0914666A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BRPI0914666A 2008-06-25 2009-06-25 otimização da solubilidade de ligantes imunológicos BRPI0914666A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7569208P 2008-06-25 2008-06-25
PCT/CH2009/000221 WO2009155725A1 (en) 2008-06-25 2009-06-25 Solubility optimization of immunobinders

Publications (1)

Publication Number Publication Date
BRPI0914666A2 true BRPI0914666A2 (pt) 2015-10-20

Family

ID=41228195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914666A BRPI0914666A2 (pt) 2008-06-25 2009-06-25 otimização da solubilidade de ligantes imunológicos

Country Status (21)

Country Link
US (3) US9556265B2 (pt)
EP (2) EP2307455B1 (pt)
JP (3) JP5745720B2 (pt)
KR (2) KR101790567B1 (pt)
CN (2) CN105418763A (pt)
AU (1) AU2009264566B2 (pt)
BR (1) BRPI0914666A2 (pt)
CA (1) CA2728829C (pt)
CY (2) CY1119626T1 (pt)
DK (2) DK3241843T3 (pt)
ES (2) ES2884117T3 (pt)
HR (2) HRP20171250T1 (pt)
HU (2) HUE056090T2 (pt)
LT (2) LT3241843T (pt)
MX (2) MX346024B (pt)
PL (2) PL2307455T3 (pt)
PT (2) PT2307455T (pt)
RU (3) RU2514658C2 (pt)
SI (2) SI3241843T1 (pt)
WO (1) WO2009155725A1 (pt)
ZA (1) ZA201008595B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101790567B1 (ko) 2008-06-25 2017-10-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
CN109293768A (zh) * 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2670778A1 (en) * 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
KR102345999B1 (ko) 2012-11-05 2021-12-30 델레넥스 쎄라퓨틱스 아게 Il-1 베타 결합성분
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
WO2014124677A1 (en) * 2013-02-15 2014-08-21 Esbatech - A Novartis Company Llc Acceptor framework for cdr grafting
EP2958939A1 (en) * 2013-02-20 2015-12-30 ESBATech - a Novartis Company LLC Acceptor framework for cdr grafting
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CA2918191A1 (en) * 2013-09-06 2015-03-12 F. Hoffmann-La Roche Ag Method for improving antibody stability
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
ES2685917T3 (es) * 2015-10-21 2018-10-15 Trinseo Europe Gmbh Dienos funcionalizados con aminosilano para el uso en la funcionalización de polímeros elastoméricos
BR112018067698A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag células modificadas para imunoterapia
CA3208905A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
WO2023110918A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
CN1300173C (zh) 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
PL195870B1 (pl) 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
ES2225269T3 (es) 1999-12-28 2005-03-16 Esbatech Ag Intracuerpos con esqueleto definido que es estable en un ambiente reductor y aplicaciones de los mismos.
NZ520622A (en) * 2000-02-25 2004-08-27 Us Gov Health & Human Serv Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60236861D1 (de) 2001-04-26 2010-08-12 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US6905608B2 (en) 2002-01-22 2005-06-14 Exergy Technologies Corporation Advanced electrodeionization for fluid recycling
EP1506236B1 (en) 2002-05-22 2013-01-23 ESBATech - a Novartis Company LLC Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
KR20160114727A (ko) * 2003-05-30 2016-10-05 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
WO2006083275A2 (en) 2004-05-21 2006-08-10 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
CA2609999C (en) 2005-06-07 2017-05-30 Esbatech Ag Stable and soluble antibodies inhibiting tnf.alpha.
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
PT2164961E (pt) 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Manipulação baseada em sequências e otimização de anticorpos de cadeia única
CN103435696B (zh) 2007-06-25 2016-10-12 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
KR101790567B1 (ko) 2008-06-25 2017-10-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화

Also Published As

Publication number Publication date
HRP20211356T1 (hr) 2021-11-26
US20170096482A1 (en) 2017-04-06
HRP20171250T1 (hr) 2017-10-20
CN102076715A (zh) 2011-05-25
SI3241843T1 (sl) 2021-11-30
LT3241843T (lt) 2021-09-27
PT3241843T (pt) 2021-09-10
RU2011102548A (ru) 2012-07-27
EP2307455A1 (en) 2011-04-13
US10221237B2 (en) 2019-03-05
JP5745720B2 (ja) 2015-07-08
HUE034827T2 (en) 2018-03-28
RU2014104577A (ru) 2015-08-20
KR20110022714A (ko) 2011-03-07
PT2307455T (pt) 2017-07-03
PL2307455T3 (pl) 2017-09-29
ZA201008595B (en) 2012-02-29
MX346024B (es) 2017-03-02
CN102076715B (zh) 2018-06-19
KR101790567B1 (ko) 2017-10-26
JP2016128517A (ja) 2016-07-14
WO2009155725A1 (en) 2009-12-30
ES2884117T3 (es) 2021-12-10
AU2009264566A1 (en) 2009-12-30
CN105418763A (zh) 2016-03-23
US20190169284A1 (en) 2019-06-06
CA2728829C (en) 2018-01-02
SI2307455T1 (sl) 2017-07-31
MX2011000074A (es) 2011-02-24
EP2307455B1 (en) 2017-03-22
DK2307455T3 (en) 2017-07-10
US9556265B2 (en) 2017-01-31
ES2629345T3 (es) 2017-08-08
CA2728829A1 (en) 2009-12-30
CY1124644T1 (el) 2022-07-22
KR101650165B1 (ko) 2016-08-22
EP3241843B1 (en) 2021-07-28
JP2011525496A (ja) 2011-09-22
CY1119626T1 (el) 2018-04-04
LT2307455T (lt) 2017-06-26
AU2009264566B2 (en) 2014-05-08
RU2514658C2 (ru) 2014-04-27
JP2014111667A (ja) 2014-06-19
KR20160083129A (ko) 2016-07-11
RU2653441C2 (ru) 2018-05-08
DK3241843T3 (da) 2021-09-06
PL3241843T3 (pl) 2021-12-27
US20110268728A1 (en) 2011-11-03
HUE056090T2 (hu) 2022-01-28
RU2018112257A (ru) 2019-10-09
US11046757B2 (en) 2021-06-29
EP3241843A1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
BRPI0914666A2 (pt) otimização da solubilidade de ligantes imunológicos
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI1006128A2 (pt) derivados de sulfonamida
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
FI20096144A0 (fi) Ulkovalaisu
DK2397480T3 (da) Diazepindionderivat
BRPI0914759A2 (pt) derivado de alquil pirimidin-4-ona substituída
DK2078895T3 (da) Belysningssystem
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
DK2387580T3 (da) Deoxyactagardinderivater
BRPI1005412A2 (pt) lâmpada
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1015957A2 (pt) Lanche impregnado de sabor de castanha
BRPI0922652A2 (pt) Derivados de quinazolinamida
ATE557242T1 (de) Leuchte
BRPI0919791A2 (pt) derivados de alternan
BRPI0909425A2 (pt) derivado de hidroxiquinoxalinacarboxamida
BR112012005828A2 (pt) luminária
FR2953703B1 (fr) Miroir eclairant
BRPI1007893A2 (pt) derivado de cianopirimidina
BRPI0910253A2 (pt) derivados de 2-aminoquinolina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements